Cargando...
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
BACKGROUND: Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally used for dose escalation decisions in Phase I oncology trials. With molecularly targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is considered increasingly relevant. METHODS: We conducted a...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6188052/ https://ncbi.nlm.nih.gov/pubmed/30338038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26104 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|